Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + VCd in Newly Diagnosed MM with Severe Renal Impairment
NCT05147493Phase 2Unknown
- Sponsor
- Hellenic Society of Hematology
- Start
- Apr 2022
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Primary endpoint: Renal Response Rate at 6 months. Status: unknown.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05147493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147493.